Clinical Observation on the Efficacy of Babaodan Combined with Interventional Therapy for Primary Hepatocellular Carcinoma

Objective To observe the clinical effect of Babaodan combined with transcatheter arterial chemoembolization （TACE） therapy for primary hepatocellular carcinoma. Methods Selected patients were randomly assigned to two groups. One group accepted TACE only and the other group accepted TACE and took 2 Babaodan capsules orally 3 times a day for 8 weeks. Results After 8 weeks＇ treatment, the size of the tumors and the alpha foetal protein （AFP） concentration in all the patients in the two groups diminished and was not significantly different between the two groups （P〉0.05）. The ratio of stability and improvement in the traditional Chinese medicine （TCM） syndrome was higher in the Babaodan plus TACE group than it was in the TACE only group （P〈0.05）. There were more complications in the TACE only group than in the Babaodan plus TACE group. The one-year survival rate in the Babaodan plus TACE group was higher than in the TACE group （P〈0.05）. Conclusion Babaodan can improve TCM syndrome, reduce complications and prolong survival of patients with primary hepatocellular carcinoma.     

Hepatic falciform artery

The hepatic falciform artery is an occasional terminal branch of the left or middle hepatic artery, and may provide an uncommon but important collateral route when the principal visceral arteries are occluded.     

血浆血管内皮细胞生长因子与肝细胞癌临床特征的相关性

目的通过检测肝细胞癌(HCC)患者肝动脉栓塞术前血浆血管内皮细胞生长因子(VEGF),考察VEGF表达与肿瘤大小、边界、门脉癌栓、远隔转移之间的相关性。方法收集介入治疗前HCC患者46例,VEGF定量检测采用双抗体夹心酶ABC ELISA法。根据血浆VEFG表达水平将患者分为阳性组(32例)和阴性组(14例),对肿瘤大小、边界、门脉癌栓、远隔转移情况进行组间对比。CT和DSA间接门脉造影获得的图像进行对比评估。结果VEGF阳性表达率69.56%(32/46),阴性表达率30.44%(14/46)。VEGF阳性组肿瘤直径>5cm者26例(81.25%),阴性组12例(85.75%),两组间无显著性差异(P>0.05)。CT片上阳性组肿瘤边界清楚15例(46.88%),阴性组边界清楚8例(57.14%),组间无显著性差异。阳性组门脉癌栓发生率62.50%(20/32),阴性组14.29%(2/14),两组间有极显著性差异(P<0.01)。阳性组远隔转移8例;阴性组无远隔转移,经检验P<0.05。结论血浆VEGF高表达可以提示门脉癌栓或远隔转移的存在,而与肿瘤大小、边界无关。血浆VEGF可能成为观察肿瘤门脉癌栓及远隔转移的指标。     

肝动脉解剖变异在中晚期肝癌介入治疗中的意义

目的 探讨放射学肝动脉解剖变异及其在中晚期肝癌介入导管治疗中的临床意义。方法 回顾性分析125例中晚期肝癌肝动脉造影表现及其介入治疗资料。结果 125例中107例(85．6％)有典型肝动脉分布。肝动脉变异18例(14．4％)，其中肝右动脉变异10例(8％)，而又以肝右动脉始于肠系膜上动脉者最多，占6．4％。副肝左动脉变异1例(0．8％)。肝左动脉和肝右动脉同时变异2例(1．6％)。肝总动脉变异3例(2．4％)。胃十二指肠动脉起自肝右动脉和腹腔动脉各1例(1．6％)。对123例成功进行了肝动脉化疗栓塞，2例肝右动脉变异因角度关系超选插管未成功。结论 认识肝动脉解剖变异有助于提高插管的成功率和中晚期肝癌的介入治疗疗效。     

Diagnosis and therapy for primary hepatic carcinoma: Transcatheter inferior phrenic arteriography and chemoembolization

Summary Transcatheter inferior phrenic arterial (IPA) and hepatic arteriography was performed on 38 patients with advanced primary hepatic carcinoma (PHC) with blood supplied by IPA and hepatic artery. 18 patients received single treatment with hepatic arterial infusion (HAI) or embolization (HAE) 20 received double treatment with IPA and hepatic arterial infusion or embolization. The results show that the double treatment is superior to the single one. The angiographic features and mechanism of parasitization of inferior phrenic arterial supply to PHC were also discussed.     

Hepatocellular carcinoma: Efficacy of transcatheter oily chemoembolization in relation to macroscopic and microscopic patterns of tumor growth among 100 patients with partial hepatectomy

Purpose: To evaluate the efficacy of transcatheter oily chemoembolization (TOCE) for hepatoceliular carcinoma (HCC) on the basis of microscopic and macroscopic findings postembolization. Methods: HCCs ranging in size from 0.5 to 13 cm (mean 3.6 cm) were obtained from partial hepatectomies of 100 consecutive patients who had undergone TOCE between 20 and 246 days (mean 59.5 days) prior to surgery. The efficacy of TOCE was assessed on the basis of the necrotic to live cell ratio of the tumors. The microscopic pattern of tumor growth was grouped into expanding type (complete capsule formation) and replacing type (incomplete or no capsule). There were five types of macroscopic groupings: single nodule, single nodule with extranodular growth (SNE), contiguous and noncontiguous multinodular, and massive growth type. Results: Among 79 cases with the expanding type, 29 (37%) had 100% HCC necrosis, but none with 100% necrosis were in the replacing type. By macroscopic grouping, the efficacy of TOCE decreased from the single nodule type (50% of patients had 100% necrosis) to the SNE type (21%), and the other types (9%).     

立体定向适形放疗对中晚期肝癌的疗效观察

目的评价立体定向适形放疗对中晚期肝癌的治疗效果。方法对中晚期肝癌患者经立体定向适形放疗及肝动脉 栓塞化疗（ＴＡＥ）后癌块最大直径、血清甲胎蛋白（ＡＦＰ）及血白细胞、肝功能的变化情况进行对比分析。立体定向适形放 疗组（Ａ组）２１例,其中肝功能Ｃｈｉｌｄ Ａ级１３例、Ｂ级８例,癌块直径小于５ ｃｍ ２例、大于１０ ｃｍ ６例、５～１０ ｃｍ １３例。 ＴＡＥ组（Ｂ　组）２０例,Ｃｈｉｌｄ Ａ级 １２例、Ｂ级 ８例,癌块直径小于 ５ ｃｍ ５例、大于 １０ ｃｍ ３例、５～１０ ｃｍ １２例。结果两组 瘤体平均直径缩小值、瘤体直径缩小率、血ＡＦＰ降低率、白细胞减少发生率及肝功能改变发生率分别为,Ａ组：（２．５８±１．８０）ｃｍ、 ６６．６７％、８６．６％、１９．０５％和９．５２％;Ｂ组：（１．２０±０．６８）ｃｍ、３０％、４３．７５％、５０％和６０％。两组差异有显著性意义。结论立体定 向适形放疗是治疗不能手术的中晚期肝癌较好的方法之一,且副反应发生率低。     

基于术前MRI影像组学特征预测肝癌经肝动脉化疗栓塞治疗的反应性

目的 探索术前MRI影像组学特征预测肝细胞癌（hepatocellular carcinoma,HCC）对经肝动脉化疗栓塞（transcatheter arterial chemoembolization,TACE）治疗反应性的可行性。方法 回顾性收集2016年3月至2018年4月经临床或病理确诊、并在温州医科大学附属第五医院接受TACE治疗的中晚期HCC患者86例,采用随机数字表法分为训练组（n=59）及验证组（n=27）,基于ITK-SNAP软件在术前T2WI图像勾画肿瘤感兴趣区,使用GE AI-Kit软件提取影像特征;经最小绝对收缩与选择算子（LASSO）回归筛选最优的特征子集,并构建TACE反应性预测模型;利用受试者工作特征（ROC）曲线、校准曲线及决策曲线分析评价模型的诊断效能和临床应用价值。结果 共筛选出8个影像学特征与TACE反应性相关,并成功构建预测模型。训练组中,该模型的ROC曲线下面积（AUC）为0.838（95%CI 0.737～0.939）,灵敏度为74.1%,特异度为84.4%;在验证组中,AUC为0.794（95%CI 0.604～0.985）,灵敏度为75.0%,特异度为80.0%。校准曲线显示该模型在训练组和验证组的预测概率与实际概率拟合较好;决策曲线分析显示该模型在0.1～1.0的阈值范围内具有较高的净收益。结论 术前MRI T2WI图像影像组学特征可用于预测HCC的TACE 反应性,基于MRI T2WI图像影像特征的预测模型特异度和灵敏度较高。     

载药微球经导管动脉化疗栓塞治疗肝细胞癌研究进展

载药微球经导管动脉化疗栓塞(DEB-TACE)利用微球在靶病灶内释放化学治疗(简称化疗)药物,使靶肿瘤内药物浓度更高,而全身化疗药物浓度及不良反应降低;且微球可较完全栓塞肿瘤毛细血管网,闭塞肿瘤邻近血管,致癌细胞缺血、缺氧而坏死。本文对DEB-TACE治疗肝细胞癌(HCC)研究进展进行综述。     

大肝癌经肝动脉门静脉化疗栓塞缩小后的外科综合治疗

目的：探讨对手术不能切除的大肝癌,经选择性动脉化疗栓塞（ＴＡＣＥ）加门静脉化疗栓塞（ＰＶＣＥ）治疗缩小后,行外科综合治疗的疗效。方法：Ｅ睦动脉、,门静脉插管或经皮行ＴＡＣＥ加ＰＶＣＥ治疗大肝癌,对缩小后的４８便行手术发除１５例,Ｂ超引导经皮肝这本内无水酒精注射治疗２３例,开腹肝肿瘤深度冷冻治疗１０例,结果：ＴＡＣＥ加ＰＶＣＥ治疗后肝肿瘤由平均直径１０．６ｃｍ缩小到４．６ｃｍ,２７例ＡＦＰ阳性者１９